Mantle Cell Lymphoma Diagnosed by Conjunctival Salmon-Pink Lesion Biopsy

Matsuo, Toshihiko; Ichimura, Kouichi; Kubonishi, Shiro

doi:10.3960/jslrt.54.143

Cited by 3 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2004, Nuckel et al 56 presented 2 relapsed conjunctival EMZL cases who were treated with systemic RTX monotherapy at a dose of 375 mg/ m2 for 4 weekly infusions. Subsequently, case reports and series describing the use of single-agent systemic RTX for 4 to 10 cyc les 57,58,61,62,[65][66][67][68][69] or in combination with chemotherapeutics 59,63,64,70 or low-dose radiotherapy 60 were published.…”

Section: Immunotherapy In CLmentioning

confidence: 99%

“…There was no local recurrence in these eyes over a median follow-up of 15 months. In 2014, Matsuo et al 63 described a patient with bilateral conjunctival MCL, orbital masses, and systemic lymphadenopathy being refractory to the combination of fludarabine and cyclophosphamide; but successfully treated with intravenous RTX and bendamustine.…”

Section: Conjunctival Lymphomamentioning

confidence: 99%

See 1 more Smart Citation

Targeted Therapy and Immunotherapy for Advanced Malignant Conjunctival Tumors: Systematic Review

Serbest Ceylanoglu,

Guneri Beser,

Singalavanija

et al. 2024

Ophthalmic Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

Purpose: To review the outcomes of targeted therapy and immunotherapy in advanced conjunctival tumors, including conjunctival squamous cell carcinoma, conjunctival melanoma, and conjunctival lymphoma. Methods: A Pubmed database systematic search was performed between January 1999 and December 2022. The literature search was limited to studies published in English. Results: This review included 142 patients with advanced malignant conjunctival tumors from 42 articles. In the conjunctival squamous cell carcinoma group, 2 cases of advanced conjunctival squamous cell carcinoma treated with epidermal growth factor receptor inhibitors showed significant tumor size improvement after 7.5 months of follow-up. Among 7 cases treated with systemic immunotherapy, 5 cases (72%) had complete response (CR), 1 case (14%) showed partial response (PR), and 1 case (14%) had stable disease (SD) after 16 months. In the conjunctival melanoma group, among 18 cases treated with combined v-raf murine sarcoma viral oncogene homolog B1/mitogen-activated extracellular signal-regulated kinase inhibitors, 6 (33%) had CR, 5 (28%) had PR, 2 (11%) had SD, and 5 (28%) had progressive disease after 24.8 months of follow-up. Of 44 conjunctival melanoma cases treated with immunotherapy, 12 (28%) had CR, 9 (20%) had PR, 7(16%) had SD, and 16 (36%) had progressive disease after 14.2 months. Systemic Rituximab treatment for conjunctival lymphoma cases resulted in CR in 21 patients (63%), PR in 11 patients (33%), and SD in 1 patient (3%) after 20.5 months of follow-up. Intralesional Rituximab injections in 38 conjunctival lymphoma cases showed CR in 28 patients (75%), PR in 7 patients (19%), SD in 1 patient (2%), and progressive disease in 2 patients (4%) after 20.4 months of follow-up. Conclusions: Despite limited clinical case reports and short-term follow-ups, targeted therapy and immunotherapy have shown promising results for advanced malignant conjunctival tumors.

show abstract

Section: Immunotherapy In CLmentioning

confidence: 99%

Section: Conjunctival Lymphomamentioning

confidence: 99%

Targeted Therapy and Immunotherapy for Advanced Malignant Conjunctival Tumors: Systematic Review

Serbest Ceylanoglu,

Guneri Beser,

Singalavanija

et al. 2024

Ophthalmic Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

show abstract

“…Primary conjunctival lymphoma appears to be predominant, [5][6][7][8][9] while secondary lymphoma as sequelae to conjunctival infiltration with lymphoma at the other sites of the body is relatively rare. [10][11][12] The predominant pathological type of the primary conjunctival lymphoma is extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).…”

Section: Introductionmentioning

confidence: 99%

Spontaneous regression and rare relapse after excisional biopsy in long-term observation of 31 patients with primary conjunctival lymphoma

Matsuo,

Tanaka

2024

J Clin Exp Hematopathol

Self Cite

View full text Add to dashboard Cite

To elucidate long-term outcome in primary conjunctival lymphoma, a review was conducted of 31 consecutive patients: 21 men and 10 women with an age range of 28 to 85 (median, 61) years at presentation and follow-up periods ranging from 1 to 19 (median, 7) years. Conjunctival lymphoma was on the right side in 10 patients, on the left side in 12, and on both sides in 9. Upper, lower, or both fornix lesions in 28 patients were all diagnosed as extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), while thick nasal bulbar conjunctival lesions in 3 patients were differently diagnosed as MALT lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma, respectively. Seven patients underwent local radiation (30 Gy): as initial treatment in 5 patients and treatment for relapse in 2 patients. The remaining 24 patients were observed without additional treatment after excisional biopsy: 5 of these 24 patients showed relapse 0.5 to 6 years later and underwent excisional biopsy again that revealed MALT lymphoma. Of the 5 patients with relapse, only one with second-time relapse underwent radiation. Fluorodeoxyglucose positron emission tomography was performed in 18 patients and showed no systemic lesions: high uptake was noted in the residual conjunctival lesions of 4 patients and in the relapsed conjunctival lesions of 3 patients. One patient died of rectal cancer while no patients died of lymphoma. Observation is an option in patients with primary conjunctival lymphoma after excisional biopsy. Radiation is a treatment option in the case of relapse.

show abstract

“…We also summarized 48 patients with MCL in the literature who presented with ocular adnexal lesions in order to elucidate their clinical features. 33 - 77 …”

Section: Introductionmentioning

confidence: 99%

Bilateral Lacrimal Gland Mantle Cell Lymphoma in 11-Year Follow-Up: Case Report and Review of 48 Cases With Ocular Adnexal Presentation in the Literature

Matsuo

Tanaka

Okada

et al. 2023

Journal of Investigative Medicine High Impact Case Reports

Self Cite

View full text Add to dashboard Cite

A 63-year-old woman, with 11-year history of breast cancer, showed bilateral lacrimal gland enlargement on magnetic resonance imaging. Gallium-67 scintigraphy, as the standard at that time in 2004, demonstrated abnormally high uptake only in bilateral lacrimal glands. The lacrimal glands were extirpated and the pathological diagnosis was mantle cell lymphoma (MCL). She underwent bilateral orbital radiation, based on no uptake of gallium-67 in other sites of the body. In a month, bone marrow biopsy revealed the infiltration with MCL, positive for cyclin D1. She showed hepatic lymphadenopathy and splenomegaly, and so received 2 cycles of alternating Hyper-CVAD therapy and high-dose methotrexate with cytarabine, combined with rituximab, in 2 months, leading to complete remission. She underwent autologous peripheral blood stem cell transplantation and was well until the age of 68 years when she showed a recurrent intratracheal submucosal lesion of lymphoma and underwent one course of reduced-dose CHOP combined with rituximab. Next year, the left rib resection revealed the metastasis of breast adenocarcinoma, leading to daily oral letrozole. Further 2 years later, computed tomographic scan demonstrated multiple submucosal nodular lesions in the trachea and bronchi, together with cervical and supraclavicular lymphadenopathy, and intratracheal lesion biopsy and bone marrow biopsy proved the involvement with MCL. She underwent 2 courses of bendamustine and rituximab, resulting in complete remission but died of metastatic breast cancer at the age of 74 years. Clinical features in 48 previous cases with ocular adnexal MCL in the literature were summarized in this study.

show abstract

Mantle Cell Lymphoma Diagnosed by Conjunctival Salmon-Pink Lesion Biopsy

Cited by 3 publications

References 22 publications

Targeted Therapy and Immunotherapy for Advanced Malignant Conjunctival Tumors: Systematic Review

Targeted Therapy and Immunotherapy for Advanced Malignant Conjunctival Tumors: Systematic Review

Spontaneous regression and rare relapse after excisional biopsy in long-term observation of 31 patients with primary conjunctival lymphoma

Bilateral Lacrimal Gland Mantle Cell Lymphoma in 11-Year Follow-Up: Case Report and Review of 48 Cases With Ocular Adnexal Presentation in the Literature

Contact Info

Product

Resources

About